Evidence map›Paper›PMID 38777778›Full record

ArticleEnvironmental health and preventive medicine2024

Identification and analysis of differently expressed transcription factors in aristolochic acid nephropathy.

Yi-Feng Wu, Zhi-Yao Tang, Yi-Xuan Deng, Kun Liu, Xu-Rui Gu, Guang-Liang Zhou, Yu-Jie Huang, Xiao-Qing Lin, Lin-Yun Zhou, Xiao-Cong Zuo

Abstract read
In one paragraph

Article in Environmental health and preventive medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yi-Feng WuDepartment of Pharmacy, The Third Xiangya Hospital, Central South University.
Zhi-Yao TangDepartment of Pharmacy, The Third Xiangya Hospital, Central South University.
Yi-Xuan DengDepartment of Pharmacy, The Third Xiangya Hospital, Central South University.
Kun LiuDepartment of Pharmacy, The Third Xiangya Hospital, Central South University.
Xu-Rui GuDepartment of Pharmacy, The Third Xiangya Hospital, Central South University.
Guang-Liang ZhouDepartment of Pharmacy, The Third Xiangya Hospital, Central South University.
Yu-Jie HuangDepartment of Pharmacy, The Third Xiangya Hospital, Central South University.
Xiao-Qing LinDepartment of Pharmacy, The Third Xiangya Hospital, Central South University.
Lin-Yun ZhouDepartment of Pharmacy, The Third Xiangya Hospital, Central South University.
Xiao-Cong ZuoDepartment of Pharmacy, The Third Xiangya Hospital, Central South University.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAristolochic acid nephropathy (AAN) is a rapidly progressive interstitial nephropathy caused by Aristolochic acid (AA). AAN is associated with the development of nephropathy and urothelial carcinoma. It is estimated that more than 100 million people worldwide are at risk of developing AAN. However, the underlying mechanisms driving renal deterioration in AAN remain poorly understood, and the treatment options are limited.

methodsWe obtained GSE27168 and GSE136276 series matrix data from the Gene Expression Omnibus (GEO) related to AAN. Using the R Studio environment, we applied the limma package and WGCNA package to identify co-differently expressed genes (co-DEGs). By GO/KEGG/GSVA analysis, we revealed common biological pathways. Subsequently, co-DEGs were subjected to the String database to construct a protein-protein interaction (PPI) network. The MCC algorithms implemented in the Cytohubba plugin were employed to identify hub genes. The hub genes were cross-referenced with the transcription factor (TF) database to identify hub TFs. Immune infiltration analysis was performed to identify key immune cell groups by utilizing CIBERSORT. The expressions of AAN-associated hub TFs were verified in vivo and in vitro. Finally, siRNA intervention was performed on the two TFs to verify their regulatory effect in AAN.

resultsOur analysis identified 88 co-DEGs through the "limma" and "WGCNA" R packages. A PPI network comprising 53 nodes and 34 edges was constructed with a confidence level >0.4. ATF3 and c-JUN were identified as hub TFs potentially linked to AAN. Additionally, expressions of ATF3 and c-JUN positively correlated with monocytes, basophils, and vessels, and negatively correlated with eosinophils and endothelial cells. We observed a significant increase in protein and mRNA levels of these two hub TFs. Furthermore, it was found that siRNA intervention targeting ATF3, but not c-JUN, alleviated cell damage induced by AA. The knockdown of ATF3 protects against oxidative stress and inflammation in the AAN cell model.

conclusionThis study provides novel insights into the role of ATF3 in AAN. The comprehensive analysis sheds light on the molecular mechanisms and identifies potential biomarkers and drug targets for AAN treatment.

Indexed as

Aristolochic AcidsKidney DiseasesTranscription FactorsActivating Transcription Factor 3AnimalsHumansMiceProtein Interaction MapsActivating Transcription Factor 3aristolochic acid IAristolochic AcidsTranscription FactorsAristolochic acid nephropathyATF3c-JUNTranscription factor

Identifiers

PMID38777778
PMCPMC11157247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.